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ABSTRACT 
Background: Clarithromycin s often a component of combination therapies 
for Helicobacter pylori eradication; however, increases in resistance rates have 
decreased the success of the treatment. 
Objective: This study was designed to determine the prevalence of H pyiori 
infection in symptomatic patients and to detect clarithromycin resistance rates 
using melting curve analysis. 
Methods: Patients cheduled for upper endoscopy at the Endoscopy Unit of 
the Department ofGastroenterology, Duzce University, Medical Faculty Hospital, 
Konuralp/Duzce, Turkey, were assessed for enrollment in the study. Two pairs 
of gastric biopsy specimens (antrum and corpus) were obtained from each 
study patient. Histopathologic examination, rapid urease test, culture, and 
polymerase chain reaction (PCR) of the specimens were used to identify 
H pylori infection. Clarithromycin resistance was detected using melting curve 
analysis. 
Results" Seventy-five patients (41 women, 34 men; mean [SD] age, 42.6 
[14.5] years [range, 17-70 years]) were included in the study. Using histo- 
pathology and rapid urease test, H pylori was detected in 40 (53.3%) of the 
75 specimens. H pylori was detected using PCR in 40 (53.3%) specimens and 
by culture in 10 (13.3%) specimens. The specificity and sensitivity of PCR and 
culture were interpreted by comparing them with the results of histopatho- 
logic examination and urease tests. The specificity and sensitivity of PCR were 
68.6% and 72.5%, respectively, and the specificity and sensitivity of culture 
were 97.1% and 22.5%, respectively. Of the 40 isolates, 21 (52.5%) were suscep- 
tible to clarithromycin, 12 (30.0%) were resistant, and a mixed susceptibility 
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pattern was detected in 7 (17.5%) specimens. Hpyiori isolates from 19 (79.2%) of 
the 24 patients who had formerly used clarithromycin showed clarithromycin 
resistance. 
Conclusions: The prevalence of H pylori infection was 53.3% for the sympto- 
matic patients in this study, and 47.5% of the isolates showed clarithromycin 
resistance using melting curve analysis. The PCR-based system used in this study 
was accurate for the detection of Hpylori infection as well as clarithromycin sus- 
ceptibility testing directly in biopsy specimens. (Curr Ther Res Clin Exp. 2007;68: 
151-160) Copyright © 2007 Excerpta Medica, Inc. 
Key words: Helicobacter pylori, clarithromycin resistance, melting curve analy- 
sis, PCR. 
INTRODUCTION 
Helicobacter pylori bacteria is a frequent cause of chronic infection worldwide, 
especially in developing countries. 1 This pathogen causes both intestinal and 
extra-intestinal complaints. Eradication regimens for H pylori usually contain 
2 antibiotics, and the macrolide drug clarithromycin is often one of the drugs 
used. However, resistance to clarithromycin has increased, leading to decreased 
treatment success. A high rate of Hpylori resistance to clarithromycin has been 
observed. Previous macrolide use has been reported to be an important risk 
factor for clarithromycin resistance. 2-4 
Clarithromycin resistance of H pylori is caused by point mutations of the 
23 soluble RNA gene, the main component of the 50S ribosomal subunit, most- 
ly at positions 2142 and 2143 (2142A~G, 2142A~C, 2142A~T; 2143A~G, 
2143A~C) in the peptidyltransferase region of the variable domain. These point 
mutations prevent the drug from binding with H pylori. ~ The melting curve 
analysis method is a real-time polymerase chain reaction (PCR) assay that can 
be used to detect clarithromycin resistance. This method allows rapid isolation 
of H pylori DNA directly from gastric biopsies as well as detection of the most 
common point mutations that confer resistance to clarithromycin. 6 
The aim of this study was to determine the prevalence of H pyiori infection in 
symptomatic patients undergoing endoscopy and to determine the clarithromycin 
resistance rate using the melting curve analysis method. 
PATIENTS AND METHODS 
Patients 
Patients coming to the Endoscopy Unit of the Department ofGastroenterology, 
Duzce University, Medical Faculty Hospital, Konuralp/Duzce, Turkey, for upper 
endoscopy were asked to participate in the study. Patient inclusion criteria 
were a history of upper gastrointestinal tract symptoms that were suggestive of 
dyspepsia nd the possibility of previous ulceration. Patients who had medical 
contraindications for the biopsy procedure and those who used antimicrobials 
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or proton pump inhibitor drugs within 2 weeks before the study were excluded. 
Previous use of clarithromycin was noted. The ethics committee of the hospital 
approved the study. All patients were required to provide written informed con- 
sent prior to study participation. 
Gastric Biopsy Specimens 
Every patient underwent upper endoscopy during which a total of 4 gastric 
biopsy specimens were taken from the antrum (2) and the corpus (2). One pair 
of samples (1 antrum and I corpus) was subjected to histopathologic examination 
and stained with hematoxylin-eosin to identify H pylori using light microscopy. 
The other pair of samples was placed in 2 mL of 0.85% normal sterile saline, 
immediately transported on ice to the laboratory, and processed within 30 min- 
utes for bacteriologic examination. All samples were subjected to the PCR pro- 
cedure, a rapid urease test, and cultured. 
Culture and Identification of Helicobacter pylori 
Biopsy specimens were cultured on Columbia agar containing 7% laked 
horse blood (lnvitrogen, Auckland, New Zealand) with Dent H pylori antibiotic 
supplement (Oxoid, Hampshire, United Kingdom) and were incubated at 37°C 
for up to 10 days in anaerobic jars (without catalyst) with CampyGen packs 
(Oxoid). H pylori colonies were identified by their characteristic morphology, 
positive urease test, and appearance of cells recovered after Gram staining. 7 
H pylori NCTC 11637 was used as a positive control. 
Helicobacter pylori Detection in Gastric Biopsy Specimens 
For each patient, a pair of biopsy samples was stored at-40°C up to the day 
of the PCR, which was performed at Metis Biotechnology Laboratory (Ankara, 
Turkey). DNA was extracted from homogenized biopsy samples using the 
phenol-chloroform extraction method, s H pylori DNA was screened using a 
nested PCR amplification method for a portion of the 23S ribosomal RNA 
(rRNA) gene. Five microliters of extracted DNA was added to each PCR ampli- 
fication reaction. 
The reaction was performed using outer primers whose nucleotide sequence 
was derived from a known sequence of the 23S rRNA gene: Hp 23 OF lpp (the 
outer forward primer): 5'-AACGGTCCTAAGGTAGCGAA-3'; CRL 2 (the outer reverse 
primer): 5'-ACACTCAACTI'GCGATrCC-3', which generates a 408-bp product; CRLF 1 
(the inner forward primer): 5'-ATGAATGGCGTAACGAGAT-3'; and Hp 23R (the 
inner reverse primer): 5'-GTGCTAAGTI'GTAGTAAAGGT-3', which generates a 126-bp 
product. 
The PCR amplification reaction mixture (50 pL) contained the following: 
nuclease-free water 36.3 pL, 10 × PCR buffer 5 pL, deoxyribonucleoside triphos- 
phates 0.5 pL (10 mM), Taq polimer~z 0.2 pL (5 U/pL, Sigma, Steinheim, 
Germany), primers 0.5 pL (100 pmol/pL), magnesium 2.5 mM, and a 5-pL DNA 
sample. The PCR cycle (Techne, Cambridge, United Kingdom) conditions were 
153 
CURRENT THERAPEUTIC RESEARCH 
as follows: 1 cycle at 94°C for 5 minutes; 30 cycles each at 94°C for 30 seconds, 
55°C for 45 seconds, and 72°C for 1 minute; 1 cycle 72°C for 5 minutes. Negative 
and positive controls were Campylobacterjejuni ATCC 33560 and H pylori NCTC 
11637, respectively. 
The PCR products were analyzed using gel electrophoresis with 2% (w/v) 
agarose stained in ethidium bromide 0.5 mg/L and examined by ultraviolet 
transillumination. 
Real-time PCR amplification and melting curve analysis of the H pylori 23S 
rRNA gene were performed. A real-time PCR hybridization assay was used to 
detect point mutations conferring resistance to clarithromycin on the outer 
PCR products obtained from gastric biopsies that were found to be positive for 
H pylori. The method included amplification of a fragment of the H pylori 23S 
rRNA gene coupled with simultaneous detection of the product by probe hy- 
bridization and analysis of the melting curve using real-time PCR. 
Real-time PCR assay was used to detect clarithromycin resistance-associated 
point mutations on the 23S rRNA gene using primers, probes, and reaction con- 
ditions described by Chisholm et al. 9 After amplification of the 96-bp region, 
clarithromycin resistance-related mutations of 2143A~C, 2143A~G, and 
2144A~G were analyzed using melting curve analysis with LightCycler software 
version 3.5.3 (LightCycler, Mannheim, Germany). Melting point peaks of 82°C 
to 86°C found H pyiori in the sample. Probe melting point peaks of positive 
samples were analyzed using the same method. Sensitive strains, 2143A~C, 
2143A~G, 2144A~G, gave peaks of-65°C,-60°C, and-55°C, respectively. 
Statistical Analysis 
Histopathologic examination and urease tests were considered to be the gold 
standard. The results of PCR and culture were interpreted by comparing them 
with the results of histopathologic examination and urease tests. The sensitiv- 
ity and specificity of the tests were evaluated statistically. Statistical analysis 
was performed using SPSS version 13.0 (SPSS Inc., Chicago, Illinois). StatCalc 6.0 
0~pi Info TM, Centers for Disease Control and Prevention, Atlanta, Georgia) was used 
to calculate the sample size. The sample comprised 78 patients, given a popu- 
lation of 312,000 people, a 90% prevalence of H pylori infection in symptomatic 
people, and a 80% confidence level. 
RESULTS 
A total of 78 patients were approached to participate in the study. Three pa- 
tients were excluded because they were receiving antimicrobial therapy for 
respiratory tract infections. Thus, 75 patients (41 females, 34 males; mean [SD] 
age, 42.6 [14.5] years [range, 17-70 years]) were included in the study. Thirty- 
two (42.7%) of the patients had a history of clarithromycin use. 
Of the patients tudied, 40 (53.3%) were identified as having Hpylori infection 
by histopathologic examination and rapid urease test, whereas 35 (46.7%) showed 
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no evidence of H pylori infection. Of the 40 patients with H pylori infection, 
24 (60.0%) stated they had previously used clarithromycin. 
When the paired specimens for the 40 patients with H pylori infection were 
analyzed by PCR and culture, H pylori was detected by PCR in 40 (53.3%) speci- 
mens and by culture in 10 (13.3%) (Table). PCR products of the anticipated size 
(294 bp) were obtained from biopsy specimens from both the antrum and cor- 
pus of all positive samples. 
Compared with histopathology and rapid urease test for the detection of 
Hpylori, the specificity and sensitivity of PCR were 68.6% and 72.5%, respectively, 
and the specificity and sensitivity of culture were 97.1% and 22.5%, respectively. 
The clarithromycin resistance rates of H pylori in our study (n = 40), as 
measured using melting curve analysis, were as follows: 21 (52.5%) suscepti- 
ble, 12 (30.0%) resistant, and 7 (17.5%) mixed susceptibility (resistant + 
susceptible). Among the patients who had previously used clarithromycin, 
79.2% (19/24) had clarithromycin-resistant strains. 
DISCUSSION 
H pylori colonizes the mucosa of the human stomach, where it can establish 
long-term infection that is associated with acute or chronic gastric inflamma- 
tion that may progress to peptic ulcer disease, atrophic gastritis with intestinal 
metaplasia, or gastric cancer.l°,~ 1 A variety of clinical outcomes of H pylori infec- 
tion are associated with both host factors and bacterial virulence factors. ~° 
In developing countries, 70% to 90% of the population have been found to 
have H pylori infection. 11 In developed countries, the prevalence of infection 
is lower. Transmission can occur by iatrogenic, fecal-oral, and oral-oral routes. 
H pylori is able to colonize and persist in a unique biological niche within the 
gastric lumen. 11 
Several diagnostic assays for H pyiori detection are currently available. In- 
vasive methods requiring gastric endoscopy include rapid urease testing, cul- 
ture, histopathology, and molecular diagnostics. Noninvasive approaches 
include fecal antigen detection, serologic testing for immunoglobulin G, and 
urea breath testing. ~2 The noninvasive methods have recently gained in impor- 
Table. The results of histopathology + rapid urease test, polymerase 
chain reaction (PCR), and culture in symptomatic patients under- 
going upper endoscopy (N = 75). Values are no. (%). 
Test Positive Negative 
Histopathology + 40 (53.3) 35 (46.7) 
rapid urease test 
PCR 40 (S3.3) 3S (46.7) 
Culture 10 (13.3) 65 (86.7) 
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tancelS; however, no information about antibiotic resistance has been obtained 
using these tests. 
Histopathology is the gold standard for diagnosing H pylori infection and is 
generally more sensitive than culture. 13 Although histopathology allows 
direct visualization of the organism and the extent and nature of tissue 
involvement, it is associated with several problems. If gastritis is patchy and 
a biopsy is performed on a non-infected area or if only a small number of 
organisms are present, the sensitivity declines. Moreover, the examination 
requires 1 to 3 days to complete. Culture permits determination of anti- 
microbial susceptibilities and pathogenic features of isolates. The disadvan- 
tages of culture include the special conditions required to transport the speci- 
men, the use of complicated media with particular maintenance conditions, 
the need for specific incubation conditions, and the length of time necessary 
to obtain a result. 9 Urease detection is rapid, but increased sensitivity 
requires longer incubation and bacterial overgrowth may cause false-positive 
results. 14 The PCR method allows rapid isolation of H pyiori directly from gas- 
tric biopsies and detects the most common point mutations that confer resis- 
tance to clarithromycin. 6 PCR is also the most accurate method among the 
biopsy-based tests used to detect H pylori infection in patients with bleed- 
ing peptic ulcers, although blood may reduce the sensitivity of all biopsy- 
based tests. 15 In clinical practice, the simple, rapid PCR assay used in this 
study might be of great value, especially when the emerging problem of 
clarithromycin-resistant strains is being considered, and may have a signifi- 
cant impact on patient management. 
Our analysis revealed that the specificity and sensitivity of PCR were 68.6% 
and 72.5%, respectively, and the specificity and sensitivity of culture were 97.1% 
and 22.5%, respectively. 
Eradication therapy is recommended for patients with peptic ulcer disease. 
The first-line regimen usually consists of a 2-drug therapy, with clarithromycin 
being one of the most widely used components in these treatments. 6 The MIC 
of clarithromycin is low and is relatively unaffected by lowering the pH. The 
drug reaches a high concentration i  gastric mucosa with a high degree of bind- 
ing to H pyiori ribosomes. 16 
Resistance of H pylori to clarithromycin is mainly due to an adenine-to-guanine 
transition at positions 2142 and 2143 and to an adenine-to-cytosine transversion at 
position 2142, which are included in the peptidyltransferase loop of the 23S rRNA 
gene. 17 The most frequently (98%) observed mutations are 2142A~ and 2143A~G, 
with the 2142A--~C mutation being much rarer (1.6%). 18 Other mutations (2115A--~G, 
2141G~A, and 2717T~C) have been described but appear to be infrequent. 19,2° 
Several methods are available to test H pyiori drug susceptibility, including 
the disc test, the E test, the microplate method, the agar plate dilution method, 
and PCR-based techniques. The E test is the standard method used in European 
countries and the United States, while no standard method of Hpylori drug sus- 
ceptibility testing has been established in Japan. 21 Several PCR-based methods 
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(eg, PCR-restriction fragment length polymorphism, PCR-DNA-enzyme immuno- 
assay, reverse hybridization line probe assay, and real-time PCR methods 
combined with melting curve analysis by biprobes and hyprobes) have been 
performed with cultured strains or biopsies to determine susceptibility to cla- 
rithromycin. 22 Some of the advantages of real-time PCR are rapidity, low con- 
tamination rate because of a closed-tube system, and the possibility of accurate 
quantification of the DNA target. 23 Melting curve analysis is a real-time PCR 
assay that can be used directly on gastric biopsies to detect he most common 
point mutations occurring in the 23S rRNA gene of H pylori that confer resis- 
tance to clarithromycin. The entire procedure requires only 2 hours from the 
time specimens are received, from the isolation of DNA from the biopsies to the 
detection of the mutations. 6 The identification of specific point mutations in the 
23S rRNA gene has enabled the development of molecular tests that allow deter- 
mination of clarithromycin resistance directly from the biopsies. The 3 most 
common mutations (2142A~G, 2143A~G, and 2142A~C) are detectable direct- 
ly from gastric biopsy specimens, thus avoiding the delay associated with culture- 
based susceptibility testing. 9 In this study, melting curve analysis allowed us to 
rapidly determine the susceptibilities of all gastric biopsy isolates, overcoming 
the delays associated with conventional culture methods for H pylori identifica- 
tion and susceptibility testing. 
The frequency of antibiotic resistance has been found to vary widely by geo- 
graphical regions and subgroups within study populations. 14'24 The global pri- 
mary resistance rate for clarithromycin was found to be 9.9%. However, notable 
differences were observed when clarithromycin resistance rates were broken 
down by regions in Europe (ie, 4.2% in Northern Europe, 9.3% in Central/Eastern 
Europe, and 18% in Southern Europe). 3,25 A systematic review of the studies per- 
formed in Canada before the year 2000 estimated resistance to be >4%. How- 
ever, resistance is reported as 10% to 15% in the United States, regardless of 
region. In the Middle East, prevalence rates of 5.4% in Israel and 17% in 
Iran have been reported. In the Far East, the prevalence is higher in Japan 
(11%-12%) than in Hong Kong (4.5%) and Korea (5%-6%). 25 
The prevalence of primary- and acquired-clarithromycin resistance is in- 
creasing worldwide, jeopardizing the success of these treatments. 6 For exam- 
ple, the resistance rates of H pylori to clarithromycin in Beijing were 10.0% 
(5/50) in 1999 to 2000 and 18.3% (20/109) in 2001 to 2002 with increasing resis- 
tance rates. 26 In Japan, use of clarithromycin i creased 4-fold between 1993 and 
2000, which resulted in a similar 4-fold increase in the resistance rate. 27 
In Turkey, resistance rates of H pylori differ, ranging from 5% to 24.2%. 28-30 In 
these studies, resistance was detected using microbiological techniques, such 
as the E test. Baglan et al ~6 detected clarithromycin resistance in 27.6% of iso- 
lates using PCR Restriction Fragment Length Polymorphism, a technique in 
which organisms may be differentiated by analysis of patterns derived from 
cleavage of their DNA. Our results, with 30.0% clarithromycin resistance and 
17.5% mixed susceptibility, support hose findings. The increase in the preva- 
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lence of resistant H pylori isolates as a result of widespread oral therapy with 
macrolides for presumptive respiratory or gastrointestinal tract infections has 
been reported. 2-4,17 Our resistance rates might be related to the frequent con- 
sumption of clarithromycin, as 60.0% of the patients with H pylori infection 
stated they had previously used the drug and resistance was detected in 79.2% 
of these patients. 
CONCLUSION 
The prevalence of Hpylori infection was 53.3% for patients who had met the cri- 
teria for endoscopy, and 47.5% of the isolates howed clarithromycin resistance 
using the melting curve analysis method. Sixty percent of the patients with 
H pyiori infection had a history of previous clarithromycin use. In evaluating 
clarithromycin resistance, the PCR-based system used in this study allowed the 
accurate detection of H pylori infection and clarithromycin susceptibility test- 
ing directly in biopsy samples. 
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